Cargando…
The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1
BACKGROUND: Leflunomide is a low-molecular-weight compound that is widely used in the treatment of rheumatoid arthritis. Although leflunomide is thought to act through the inhibition of the de novo pyrimidine synthesis, the molecular mechanism of the drug remains largely unknown. We investigated the...
Autores principales: | Moon, Su-Jin, Kim, Eun-Kyung, Jhun, Joo Yeon, Lee, Hee Jin, Lee, Weon Sun, Park, Sang-Hi, Cho, Mi-La, Min, Jun-Ki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304395/ https://www.ncbi.nlm.nih.gov/pubmed/28193225 http://dx.doi.org/10.1186/s12967-017-1131-x |
Ejemplares similares
-
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function
por: Kirsch, Bernhard M, et al.
Publicado: (2005) -
The active metabolite of leflunomide, A77-1726, increases proliferation of human synovial fibroblasts in presence of IL-1β
por: Magne, D, et al.
Publicado: (2004) -
Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels
por: Fajardo-Robledo, Nicte S., et al.
Publicado: (2022) -
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes
por: Palmer, Gaby, et al.
Publicado: (2004) -
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation
por: Xu, Xiulong, et al.
Publicado: (2017)